Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Retatrutide holds considerable promise as a future treatment for obesity and potentially type 2 diabetes, based on early trial data
Unlike earlier oral agents, orforglipron does not require fasting and was approved by the FDA in April 2026 for weight loss, becoming Lilly's second FDA-approved obesity medicine and first GLP-1 pill, Foundayo
Phase III - large number of patient groups, designed to confirm the safety and efficacy of the medicine
Outcome Dr Reddys agreed to voluntarily change the brand name to Olymra, resolving the dispute temporarily while ensuring continued product availability
Eli Lilly's core tirzepatide patents don't expire until 2036-2037, and formulation patents extend through 2040
US$ 26.53
US$ 29.14
US$ 28.61
US$ 29.22
US$ 26.25
